{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:23:23Z","timestamp":1781774603264,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus infections are a significant risk factor for the development of oral cancers. While HPV vaccines have proven effective in preventing cervical cancers, their impact on oral cancers remains insufficiently examined. This systematic review assesses the effectiveness of gender-neutral HPV vaccination in reducing oral HPV rates, a key precursor to HPV-associated oral cancers, focusing exclusively on studies including gender-neutral samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA 2020 guidelines, a comprehensive search strategy was implemented, covering multiple databases, including MEDLINE and Embase, as well as grey literature and ongoing trials sources via WHO ICTRP, EUCTR and ClinicalTrials.gov. Inclusion criteria encompassed studies published between 2009 and 2025 with gender-neutral samples, oral HPV prevalence data, and vaccination status information. Quality of the included studies was assessed using the JBI Critical Appraisal Checklists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine observational studies were included, with sample sizes ranging from 394 to 9,437 participants and age ranges spanning from 18 to 70 years across multiple countries, including the United States, Australia, and Italy. Six studies reported lower prevalence of oral vaccine-type HPV (VT-HPV) among vaccinated individuals, with relative reductions ranging from 57.5% to 93.2% and an overall mean reduction of 78.5%. Lower prevalence was observed even after a single vaccine dose. In sex-stratified analyses, females showed a mean reduction of 86.8%, while males showed a mean reduction of 69.1%, with two studies reporting 100% protection among vaccinated males. Heterogeneity in outcome definitions, reporting formats, and sample overlap precluded meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first systematic review focusing exclusively on gender-neutral samples. The findings suggest that gender-neutral HPV vaccination programmes, which are associated with lower oral prevalence of vaccine-type HPV, may contribute to reducing the burden of HPV-associated oral cancers. Including males in national immunisation strategies is essential to promote equity and maximize public health impact, particularly given the higher burden of HPV-associated oropharyngeal cancers in men. Further research is required to better understand this effect, including the influence of dose number and the potential role of sex in vaccine response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO (CRD420251144148).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15979-3","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:55:15Z","timestamp":1776322515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0452-8103","authenticated-orcid":false,"given":"Lamia M.","family":"Douyat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5767","authenticated-orcid":false,"given":"Angela","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"15979_CR1","unstructured":"World Health Organization. Oral health. Geneva: WHO. 2023. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/oral-health."},{"key":"15979_CR2","unstructured":"FDI World Dental Federation. Oral health conditions. Geneva: FDI. 2020. Available from: https:\/\/www.fdiworlddental.org\/oral-health-conditions."},{"key":"15979_CR3","doi-asserted-by":"crossref","unstructured":"Bellantoni MI, Picciolo G, Pirrotta I, Irrera N, Vaccaro M, Vaccaro F et al. Oral cavity squamous cell carcinoma: an update of the pharmacological treatment. Biomedicines. 2023;11(4):1112. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10135659\/.","DOI":"10.3390\/biomedicines11041112"},{"key":"15979_CR4","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"15979_CR5","doi-asserted-by":"publisher","unstructured":"Sherman RL, Firth AU, Henley SJ, Siegel RL, Negoita S, Sung H et al. Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025;131(9):e35833. https:\/\/doi.org\/10.1002\/cncr.35833. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/cncr.35833.","DOI":"10.1002\/cncr.35833"},{"key":"15979_CR6","doi-asserted-by":"crossref","unstructured":"Tranby EP, Heaton LJ, Tomar SL, Kelly AL, Fager GL, Backley M et al. Oral cancer prevalence, mortality, and costs in Medicaid and commercial insurance claims data. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1849\u201357. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0114. Available from: https:\/\/aacrjournals.org\/cebp\/article\/31\/9\/1849\/708747\/Oral-Cancer-Prevalence-Mortality-and-Costs-in.","DOI":"10.1158\/1055-9965.EPI-22-0114"},{"key":"15979_CR7","doi-asserted-by":"crossref","unstructured":"Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. Oral Oncol. 2010;46(6):414\u2013417. https:\/\/doi.org\/10.1016\/j.oraloncology.2010.03.009. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1368837510000989#bib14.","DOI":"10.1016\/j.oraloncology.2010.03.009"},{"key":"15979_CR8","doi-asserted-by":"crossref","unstructured":"Scully C, Porter S. Oral cancer. West J Med. 2001;174(5):348\u2013351. https:\/\/doi.org\/10.1136\/ewjm.174.5.348. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1071397\/.","DOI":"10.1136\/ewjm.174.5.348"},{"key":"15979_CR9","doi-asserted-by":"crossref","unstructured":"Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy. Cancers (Basel). 2021;13(19):4912. Published 2021 Sep 30. https:\/\/doi.org\/10.3390\/cancers13194912. Available from: https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4912.","DOI":"10.3390\/cancers13194912"},{"key":"15979_CR10","doi-asserted-by":"publisher","unstructured":"Brown LM, Check DP, Devesa SS. Oropharyngeal cancer incidence trends: diminishing racial disparities. Cancer Causes Control. 2011;22(5):753\u2013763. https:\/\/doi.org\/10.1007\/s10552-011-9748-1. Available from: https:\/\/link.springer.com\/article\/10.1007\/s10552-011-9748-1.","DOI":"10.1007\/s10552-011-9748-1"},{"key":"15979_CR11","doi-asserted-by":"crossref","unstructured":"Gribb JP, Wheelock JH, Park ES. Human Papilloma Virus (HPV) and the Current State of Oropharyngeal Cancer Prevention and Treatment. Dela J Public Health. 2023;9(1):26\u201328. Published 2023 Apr 22. https:\/\/doi.org\/10.32481\/djph.2023.04.008. Available from: https:\/\/djph.org\/wp-content\/uploads\/2023\/04\/djph-91-008.pdf.","DOI":"10.32481\/djph.2023.04.008"},{"key":"15979_CR12","doi-asserted-by":"crossref","unstructured":"Galati L, Chiocca S, Duca D et al. HPV and head and neck cancers: Towards early diagnosis and prevention. Tumour Virus Res. 2022;14:200245. https:\/\/doi.org\/10.1016\/j.tvr.2022.200245. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666679022000118?via%3Dihub.","DOI":"10.1016\/j.tvr.2022.200245"},{"key":"15979_CR13","doi-asserted-by":"crossref","unstructured":"Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467\u2013475. https:\/\/doi.org\/10.1158\/1055-9965.EPI-04-0551. Available from: https:\/\/aacrjournals.org\/cebp\/article\/14\/2\/467\/257758\/Human-Papillomavirus-Types-in-Head-and-Neck.","DOI":"10.1158\/1055-9965.EPI-04-0551"},{"key":"15979_CR14","doi-asserted-by":"crossref","unstructured":"Hathaway JK. HPV: diagnosis, prevention, and treatment. Clin Obstet Gynecol. 2012;55(3):671\u2013680. https:\/\/doi.org\/10.1097\/GRF.0b013e31825caa36. Available from: https:\/\/journals.lww.com\/clinicalobgyn\/pages\/articleviewer.aspx?year=2012&issue=09000&article=00010&type=Fulltext.","DOI":"10.1097\/GRF.0b013e31825caa36"},{"key":"15979_CR15","doi-asserted-by":"crossref","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e190. https:\/\/doi.org\/10.1016\/S2214-109X(19)30488-7. Available from: https:\/\/www.thelancet.com\/journals\/langlo\/article\/PIIS2214-109X(19)30488-7\/fulltext.","DOI":"10.1016\/S2214-109X(19)30488-7"},{"key":"15979_CR16","doi-asserted-by":"publisher","unstructured":"Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612\u2013619. Available from: https:\/\/doi.org\/10.1200\/JCO.2007.14.1713.","DOI":"10.1200\/JCO.2007.14.1713"},{"key":"15979_CR17","doi-asserted-by":"crossref","unstructured":"Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660\u2013664. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6745688\/.","DOI":"10.1097\/OLQ.0000000000000193"},{"key":"15979_CR18","unstructured":"McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in Adults Aged 18\u201369: United States, 2011\u20132014. NCHS Data Brief. 2017;(280):1\u20138. Available from: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db280.pdf."},{"key":"15979_CR19","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S367-S378. https:\/\/doi.org\/10.1093\/infdis\/jiaa621. Available from: https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_4\/S367\/6378095.","DOI":"10.1093\/infdis\/jiaa621"},{"key":"15979_CR20","unstructured":"World Health Organization. WHO adds an HPV vaccine for single-dose use. 2024. Available from: https:\/\/www.who.int\/news\/item\/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use. Accessed 29 May 2025."},{"key":"15979_CR21","doi-asserted-by":"publisher","unstructured":"Amiri S, Rasekh S, Moezzi SMI, Seifi N, Fatemi SA, Fathi S et al. Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded. Infect Agent Cancer. 2025;20(1):16. Published 2025 Mar 10. https:\/\/doi.org\/10.1186\/s13027-025-00643-5. Available from: https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-025-00643-5.","DOI":"10.1186\/s13027-025-00643-5"},{"key":"15979_CR22","unstructured":"World Health Organization. Considerations for human papillomavirus (HPV) vaccine product choice. 2nd ed. Geneva: World Health Organization. 2024. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379113\/9789240100930-eng.pdf?sequence=1. Accessed 29 May 2025."},{"key":"15979_CR23","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Tsu V, Deeks SL et al. Human papillomavirus vaccine introduction\u2013the first five years. Vaccine. 2012;30 Suppl 5:F139-F148. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X12007578?via%3Dihub.","DOI":"10.1016\/j.vaccine.2012.05.039"},{"key":"15979_CR24","doi-asserted-by":"crossref","unstructured":"Palmer TJ, Kavanagh K, Cuschieri K, Cameron R, Graham C, Wilson A et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. J Natl Cancer Inst. 2024;116(6):857\u2013865. https:\/\/doi.org\/10.1093\/jnci\/djad263. Available from: https:\/\/academic.oup.com\/jnci\/article\/116\/6\/857\/7577291.","DOI":"10.1093\/jnci\/djad263"},{"key":"15979_CR25","doi-asserted-by":"publisher","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, Wang J, Roth A, Fang F et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340\u20131348. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1917338.","DOI":"10.1056\/NEJMoa1917338"},{"key":"15979_CR26","doi-asserted-by":"crossref","unstructured":"Patra S, Shand H, Ghosal S, Ghorai S. HPV and Male Cancer: Pathogenesis, Prevention and Impact. Journal of the Oman Medical Association. 2025;2(1):4. 10.3390\/joma2010004. https:\/\/doi.org\/10.3390\/joma2010004.\u00a0Available from: https:\/\/www.mdpi.com\/2813-8759\/2\/1\/4.","DOI":"10.3390\/joma2010004"},{"key":"15979_CR27","doi-asserted-by":"publisher","unstructured":"Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41):1700737. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.41.1700737.\u00a0Available from: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES.2018.23.41.1700737.","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"key":"15979_CR28","unstructured":"International Vaccine Access Center (IVAC). Johns Hopkins Bloomberg School of Public Health. Human papillomavirus vaccine. VIEW-hub by IVAC. Available from: https:\/\/view-hub.org\/vaccine\/hpv?set=target-population-sex&group=vaccine-introduction&category=hpv. Accessed 2 Jun 2025."},{"key":"15979_CR29","doi-asserted-by":"publisher","unstructured":"Macilwraith P, Malsem E, Dushyanthen S. The effectiveness of HPV vaccination on the incidence of oropharyngeal cancers in men: a review. Infect Agent Cancer. 2023;18(1):24. https:\/\/doi.org\/10.1186\/s13027-022-00479-3. Available from: https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-022-00479-3. Published 24 Apr 2023.","DOI":"10.1186\/s13027-022-00479-3"},{"key":"15979_CR30","doi-asserted-by":"crossref","unstructured":"Lechner M, Jones OS, Breeze CE, Gilson R. Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness. Lancet Infect Dis. 2019;19(2):131\u2013132. Available from: https:\/\/doi.org\/10.1016\/S1473-3099(18)30802-8, https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(18)30802-8\/fulltext.","DOI":"10.1016\/S1473-3099(18)30802-8"},{"key":"15979_CR31","unstructured":"Afrian A, Andeweg SP, Backer JA, van de Beld MJC, Beninc\u00e0 E, Benschop KSM et al. The National Immunisation Programme in the Netherlands: Surveillance and developments in 2021\u20132022. Bilthoven: RIVM; 2022. Report No.: 2022-0042. Available from: https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2022-0042.pdf."},{"key":"15979_CR32","doi-asserted-by":"publisher","unstructured":"Muhamad NA, Buang SN, Jaafar S, Jais R, Tan PS, Mustapha N et al. Achieving high uptake of human papillomavirus vaccination in Malaysia through school-based vaccination programme. BMC Public Health. 2018;18(1):1402. Published 2018 Dec 22. https:\/\/doi.org\/10.1186\/s12889-018-6316-6. Available from: https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-018-6316-6.","DOI":"10.1186\/s12889-018-6316-6"},{"key":"15979_CR33","doi-asserted-by":"publisher","unstructured":"Brotherton JM, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199(9):614-617. https:\/\/doi.org\/10.5694\/mja13.10272. Available from:\u00a0 https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.5694\/mja13.10272.","DOI":"10.5694\/mja13.10272"},{"key":"15979_CR34","doi-asserted-by":"crossref","unstructured":"Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920-1928. https:\/\/doi.org\/10.1080\/21645515.2019.1600985.\u00a0Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6746516\/.","DOI":"10.1080\/21645515.2019.1600985"},{"key":"15979_CR35","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 29 Mar 2021. https:\/\/doi.org\/10.1136\/bmj.n71. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71.long.","DOI":"10.1136\/bmj.n71"},{"key":"15979_CR36","unstructured":"Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4; Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630\u2013632. Available from: https:\/\/www.cdc.gov\/mmwr\/pdf\/wk\/mm5920.pdf."},{"key":"15979_CR37","unstructured":"Szklo M, Nieto FJ. Epidemiology Beyond the Basics. Third edition. Burlington (MA): Jones & Bartlett Learning; 2014. P. 86\u201387."},{"key":"15979_CR38","unstructured":"Joanna Briggs Institute. Checklist for Analytical Cross Sectional Studies. Adelaide: JBI. 2017. Available from: https:\/\/jbi.global\/critical-appraisal-tools. Accessed 2 Jun 2025."},{"key":"15979_CR39","unstructured":"Joanna Briggs Institute. Checklist for Cohort Studies. Adelaide: JBI. 2017. Available from: https:\/\/jbi.global\/critical-appraisal-tools. Accessed 2 Jun 2025."},{"key":"15979_CR40","doi-asserted-by":"crossref","unstructured":"Hirth JM, Chang M, Resto VA, HPV Study Group. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old). Vaccine. 2017;35(27):3446\u20133451. https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.025. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X17306333.","DOI":"10.1016\/j.vaccine.2017.05.025"},{"key":"15979_CR41","doi-asserted-by":"crossref","unstructured":"Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2018;36(3):262\u2013267. https:\/\/doi.org\/10.1200\/JCO.2017.75.0141. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5773841\/.","DOI":"10.1200\/JCO.2017.75.0141"},{"key":"15979_CR42","doi-asserted-by":"crossref","unstructured":"Brouwer AF, Eisenberg MC, Carey TE, Meza R. Multisite HPV infections in the United States (NHANES 2003\u20132014): An overview and synthesis. Prev Med. 2019;123:288\u2013298. https:\/\/doi.org\/10.1016\/j.ypmed.2019.03.040. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6534472\/.","DOI":"10.1016\/j.ypmed.2019.03.040"},{"key":"15979_CR43","doi-asserted-by":"crossref","unstructured":"Abel MK, Mann AK, Sonawane K, Kapp DS, Deshmukh AA, Chan JK. Prevalence of Oral Human Papillomavirus Infection by Number of Vaccine Doses Among US Adults. JNCI Cancer Spectr. 2021;5(6):pkab086. Published 2021 Dec 21. https:\/\/doi.org\/10.1093\/jncics\/pkab086. Available from: http:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8713009\/.","DOI":"10.1093\/jncics\/pkab086"},{"key":"15979_CR44","doi-asserted-by":"crossref","unstructured":"Berenson AB, Hirth JM, Chang M. Prevalence of Oral Human Papillomavirus Infection: Impact of Sex, Race\/Ethnicity, and Vaccination Status. Clin Infect Dis. 2022;74(7):1230\u20131236. https:\/\/doi.org\/10.1093\/cid\/ciab605. Available from: https:\/\/academic.oup.com\/cid\/article\/74\/7\/1230\/6314534.","DOI":"10.1093\/cid\/ciab605"},{"key":"15979_CR45","doi-asserted-by":"publisher","unstructured":"Brouwer AF, Campredon LP, Walline HM, Marinelli BM, Goudsmit CM, Thomas TB et al. Prevalence and determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) cohort study. PLoS One. 2022;17(5):e0268104. Published 2022 May 16. https:\/\/doi.org\/10.1371\/journal.pone.0268104. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0268104.","DOI":"10.1371\/journal.pone.0268104"},{"key":"15979_CR46","doi-asserted-by":"crossref","unstructured":"Brouwer AF, Campredon LP, Walline HM, Marinelli BM, Goudsmit CM, Thomas TB et al. Incidence and clearance of oral and cervicogenital HPV infection: longitudinal analysis of the MHOC cohort study. BMJ Open. 2022;12(1):e056502. Published 2022 Jan 3. https:\/\/doi.org\/10.1136\/bmjopen-2021-056502. Available from: https:\/\/bmjopen.bmj.com\/content\/12\/1\/e056502.long.","DOI":"10.1136\/bmjopen-2021-056502"},{"key":"15979_CR47","doi-asserted-by":"publisher","unstructured":"de Souza MMA, Hartel G, Olsen CM, Whiteman DC, Antonsson A. Oral human papillomavirus (HPV) infection and HPV vaccination in an Australian cohort. Int J Cancer. 2023;153(2):417\u2013426. https:\/\/doi.org\/10.1002\/ijc.34517. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.34517.","DOI":"10.1002\/ijc.34517"},{"key":"15979_CR48","doi-asserted-by":"crossref","unstructured":"Napolitano F, Angelillo S, Bianco A, Di Giuseppe G, Di Onofrio V, Licata F et al. Genital and Oral HPV Geno-Prevalence Measured through Urine and Saliva Samples in Young Adults in Italy. Vaccines (Basel). 2024;12(2):205. Published 2024 Feb 16. https:\/\/doi.org\/10.3390\/vaccines12020205. Available from: https:\/\/www.mdpi.com\/2076-393X\/12\/2\/205.","DOI":"10.3390\/vaccines12020205"},{"key":"15979_CR49","unstructured":"Coggon D, Rose G, Barker DJ. Epidemiology for the uninitiated. BMJ; 2003. Available from: https:\/\/www.bmj.com\/about-bmj\/resources-readers\/publications\/epidemiology-uninitiated\/8-case-control-and-cross-sectional. Accessed 2 Jun 2025."},{"key":"15979_CR50","doi-asserted-by":"crossref","unstructured":"Cavenaghi VB, Ghosn EJ, Cruz N, Rossi LM, da Silva L, Costa HO et al. Determination of HPV prevalence in oral\/oropharyngeal mucosa samples in a rural district of S\u00e3o Paulo. Braz J Otorhinolaryngol. 2013;79(5):599\u2013602. https:\/\/doi.org\/10.5935\/1808-8694.20130107. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1808869415303190?via%3Dihub.","DOI":"10.5935\/1808-8694.20130107"},{"key":"15979_CR51","doi-asserted-by":"crossref","unstructured":"Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359(9302):248\u2013252. https:\/\/doi.org\/10.1016\/S0140-6736(02)07451-2. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(02)07451-2\/fulltext.","DOI":"10.1016\/S0140-6736(02)07451-2"},{"key":"15979_CR52","doi-asserted-by":"publisher","unstructured":"Kaczmarczyk KH, Yusuf H. The impact of HPV vaccination on the prevention of oropharyngeal cancer: A scoping review. Community Dent Health. 2022;39(1):14\u201321. Published 2022 Mar 1. 10.1922\/CDH_00072Kaczmarczyk08. https:\/\/doi.org\/10.1922\/CDH_00072Kaczmarczyk08.\u00a0Available from:\u00a0 https:\/\/journals.sagepub.com\/doi\/10.1922\/CDH_00072Kaczmarczyk08.","DOI":"10.1922\/CDH_00072Kaczmarczyk08"},{"key":"15979_CR53","doi-asserted-by":"publisher","unstructured":"Dykens JA, Peterson CE, Holt HK, Harper DM. Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. Front Public Health. 2023;11:1067299. Published 2023 Feb 21. https:\/\/doi.org\/10.3389\/fpubh.2023.1067299. Available from: https:\/\/www.frontiersin.org\/journals\/public-health\/articles\/10.3389\/fpubh.2023.1067299.","DOI":"10.3389\/fpubh.2023.1067299"},{"key":"15979_CR54","doi-asserted-by":"publisher","unstructured":"Sauvageau C, Dufour-Turbis C. HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Qu\u00e9bec Immunization Committee. Hum Vaccin Immunother. 2016;12(6):1560\u20131565. https:\/\/doi.org\/10.1080\/21645515.2015.1112474. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2015.1112474.","DOI":"10.1080\/21645515.2015.1112474"},{"key":"15979_CR55","doi-asserted-by":"publisher","unstructured":"Harper DM, Alexander NM, Ahern DA, Comes JC, Smith MS, Heutinck MA et al. Women have a preference for their male partner to be HPV vaccinated. PLoS One. 2014;9(5):e97119. Published 2014 May 14. https:\/\/doi.org\/10.1371\/journal.pone.0097119. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0097119.","DOI":"10.1371\/journal.pone.0097119"},{"key":"15979_CR56","doi-asserted-by":"crossref","unstructured":"Spayne J, Hesketh T. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. BMJ Open. 2021;11(9):e052016. Published 2021 Sep 2. https:\/\/doi.org\/10.1136\/bmjopen-2021-052016.\u00a0Available from:\u00a0 https:\/\/bmjopen.bmj.com\/content\/11\/9\/e052016.long.","DOI":"10.1136\/bmjopen-2021-052016"},{"key":"15979_CR57","doi-asserted-by":"crossref","unstructured":"Ndon S, Singh A, Ha PK, Aswani J, Chan JY, Xu MJ. Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications. Cancers (Basel). 2023;15(16):4080. Published 2023 Aug 13. https:\/\/doi.org\/10.3390\/cancers15164080. Available from: https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4080.","DOI":"10.3390\/cancers15164080"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15979-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15979-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15979-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:09:12Z","timestamp":1781647752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15979-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15979"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15979-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"678"}}